TY - JOUR
T1 - Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia
T2 - Case report and review of literature
AU - Truica, Cristina I.
AU - Frankel, Stanley R.
PY - 2002
Y1 - 2002
N2 - Rhabdomyolysis is an unusual complication of chemotherapy that can lead to substantial morbidity through such complications as renal failure, infections, and disseminated intravascular coagulation. The syndrome has been described after treatment with cyclophosphamide, 5-azacytidine, interleukin-2, and interferon and after bone marrow transplantation. We report a patient with acute myeloid leukemia who developed fulminant rhabdomyolysis after treatment with a cytarabine-containing regimen. The syndrome was complicated by acute renal failure requiring hemodyalisis, respiratory insufficiency, and pancreatitis. We suggest that the muscle damage might be related to the known ability of cytarabine to trigger the release of cytochrome c from the mitochondria, which could lead to uncoupling of the oxidative phosphorylation with subsequent depletion of ATP reserves at the skeletal muscle and rhabdomyolysis.
AB - Rhabdomyolysis is an unusual complication of chemotherapy that can lead to substantial morbidity through such complications as renal failure, infections, and disseminated intravascular coagulation. The syndrome has been described after treatment with cyclophosphamide, 5-azacytidine, interleukin-2, and interferon and after bone marrow transplantation. We report a patient with acute myeloid leukemia who developed fulminant rhabdomyolysis after treatment with a cytarabine-containing regimen. The syndrome was complicated by acute renal failure requiring hemodyalisis, respiratory insufficiency, and pancreatitis. We suggest that the muscle damage might be related to the known ability of cytarabine to trigger the release of cytochrome c from the mitochondria, which could lead to uncoupling of the oxidative phosphorylation with subsequent depletion of ATP reserves at the skeletal muscle and rhabdomyolysis.
UR - http://www.scopus.com/inward/record.url?scp=0036323944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036323944&partnerID=8YFLogxK
U2 - 10.1002/ajh.10152
DO - 10.1002/ajh.10152
M3 - Article
C2 - 12210815
AN - SCOPUS:0036323944
SN - 0361-8609
VL - 70
SP - 320
EP - 323
JO - American Journal of Hematology
JF - American Journal of Hematology
IS - 4
ER -